DK0551182T3 - Fremgangsmåde til behandling af hyperproliferative karsygdomme under anvendelse af rapamycin, eventuelt i komb. med mycophe - Google Patents

Fremgangsmåde til behandling af hyperproliferative karsygdomme under anvendelse af rapamycin, eventuelt i komb. med mycophe

Info

Publication number
DK0551182T3
DK0551182T3 DK93300052T DK93300052T DK0551182T3 DK 0551182 T3 DK0551182 T3 DK 0551182T3 DK 93300052 T DK93300052 T DK 93300052T DK 93300052 T DK93300052 T DK 93300052T DK 0551182 T3 DK0551182 T3 DK 0551182T3
Authority
DK
Denmark
Prior art keywords
vascular disease
rapamycin
mycophe
comb
optionally
Prior art date
Application number
DK93300052T
Other languages
English (en)
Inventor
Randall Ellis Morris
Clare Robert Gregory
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Application granted granted Critical
Publication of DK0551182T3 publication Critical patent/DK0551182T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK93300052T 1992-01-09 1993-01-06 Fremgangsmåde til behandling af hyperproliferative karsygdomme under anvendelse af rapamycin, eventuelt i komb. med mycophe DK0551182T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81931492A 1992-01-09 1992-01-09

Publications (1)

Publication Number Publication Date
DK0551182T3 true DK0551182T3 (da) 2000-10-09

Family

ID=25227805

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93300052T DK0551182T3 (da) 1992-01-09 1993-01-06 Fremgangsmåde til behandling af hyperproliferative karsygdomme under anvendelse af rapamycin, eventuelt i komb. med mycophe

Country Status (14)

Country Link
EP (1) EP0551182B1 (da)
JP (1) JP2644955B2 (da)
KR (1) KR100276142B1 (da)
AT (1) ATE194493T1 (da)
AU (1) AU665041B2 (da)
CA (1) CA2086642C (da)
DE (1) DE69328981T2 (da)
DK (1) DK0551182T3 (da)
ES (1) ES2147740T3 (da)
GR (1) GR3034479T3 (da)
LV (1) LV12603B (da)
NZ (1) NZ245630A (da)
PT (1) PT551182E (da)
SG (1) SG47639A1 (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69403966T3 (de) 1993-07-19 2008-04-17 Angiotech Pharmaceuticals, Inc., Vancouver Anti-angiogene mittel und verfahren zu deren verwendung
EP0729471A1 (en) * 1993-11-19 1996-09-04 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
US5444072A (en) * 1994-02-18 1995-08-22 Syntex (U.S.A.) Inc. 6-substituted mycophenolic acid and derivatives
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US5605696A (en) * 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
DE69624921T2 (de) 1995-06-09 2003-09-11 Novartis Ag, Basel Rapamycinderivate
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
KR100616020B1 (ko) * 1996-03-27 2007-01-31 노파르티스 아게 맥관장애및이종이식술에서의라파마이신유도체의용도
ID18663A (id) 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
IT1289815B1 (it) 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
US6273913B1 (en) † 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7208011B2 (en) 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
PT1019111E (pt) 1998-04-27 2002-10-31 Surmodics Inc Revestimento que liberta um agente bioactivo
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6251136B1 (en) 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
US6702849B1 (en) 1999-12-13 2004-03-09 Advanced Cardiovascular Systems, Inc. Method of processing open-celled microcellular polymeric foams with controlled porosity for use as vascular grafts and stent covers
EP1582180B1 (en) 2000-10-16 2008-02-27 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7056338B2 (en) 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
US7682387B2 (en) 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US6939376B2 (en) 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7097850B2 (en) 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
EP2253339B1 (en) 2003-02-21 2011-12-28 Sorin Biomedica Cardio S.r.l. A process for producing stents and corresponding stent
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
US7303758B2 (en) * 2004-01-20 2007-12-04 Cordis Corporation Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis following vascular injury
CN1964749A (zh) 2004-04-06 2007-05-16 苏莫迪克斯公司 用于生物活性剂的涂料组合物
USD516723S1 (en) 2004-07-06 2006-03-07 Conor Medsystems, Inc. Stent wall structure
WO2007040249A1 (ja) 2005-10-06 2007-04-12 Kaneka Corporation 生体留置用ステント
AU2007271554B2 (en) 2006-07-03 2011-02-10 Hemoteq Ag Manufacture, method, and use of active substance-releasing medical products for permanently keeping blood vessels open
RU2458710C2 (ru) 2007-01-21 2012-08-20 Хемотек Аг Медицинский продукт для лечения обтураций просветов организма и для предупреждения угрожающих повторных обтураций
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
EP2245165A4 (en) 2008-01-11 2011-06-01 Massachusetts Eye & Ear Infirm TRANSGENIC CONDITIONAL STOP DIMERICABLE CASPASE ANIMALS
ES2550634T3 (es) 2009-07-10 2015-11-11 Boston Scientific Scimed, Inc. Uso de nanocristales para un balón de suministro de fármaco
JP5933434B2 (ja) 2009-07-17 2016-06-08 ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. 薬剤送達バルーンの製造方法
US8889211B2 (en) 2010-09-02 2014-11-18 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
US8669360B2 (en) 2011-08-05 2014-03-11 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (en) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
JP6278332B2 (ja) 2013-04-22 2018-02-14 スズキ株式会社 変速機の制御装置

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus

Also Published As

Publication number Publication date
NZ245630A (en) 1997-07-27
DE69328981D1 (de) 2000-08-17
HK1010332A1 (en) 1999-06-17
SG47639A1 (en) 1998-04-17
KR930016102A (ko) 1993-08-26
JPH069390A (ja) 1994-01-18
CA2086642C (en) 2004-06-15
LV12603B (en) 2001-04-20
ATE194493T1 (de) 2000-07-15
PT551182E (pt) 2000-12-29
ES2147740T3 (es) 2000-10-01
EP0551182B1 (en) 2000-07-12
DE69328981T2 (de) 2000-11-16
KR100276142B1 (ko) 2001-02-01
CA2086642A1 (en) 1993-07-10
LV12603A (en) 2001-01-20
GR3034479T3 (en) 2000-12-29
AU665041B2 (en) 1995-12-14
EP0551182A1 (en) 1993-07-14
JP2644955B2 (ja) 1997-08-25
AU3107993A (en) 1993-07-15

Similar Documents

Publication Publication Date Title
GR3034479T3 (en) Method of treating hyperproliferative vascular disease using rapamycin, eventually in combination with mycophenolic acid.
PY0101639A (es) Method of treating restenosis with rapamycin
DK0583925T3 (da) Rapamycin til behandling af Crohn's sygdom, ulcerøs colitis og ulcerøs proctitis
DK0665013T3 (da) Behandling af hyperproliferative karsygdomme
ES2085720T3 (es) Composicion que comprende heparina y rapamicina.
ATE257844T1 (de) Menschlicher wachstumsfaktor (hgf), verändert durch polyethylenglykol
FI941133L (fi) Koostumus ja menetelmä hepatiitti C:n hoitamiseksi
DK0659410T3 (da) Anvendelse af det aktive middel flupirtin til fremstilling af et lægemiddel til bekæmpelse af muskelspændinger
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
DE3789425D1 (de) Verfahren zur Kettspannungskontrolle.
DE69130586D1 (de) Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
ATE138807T1 (de) 29-demethoxyrapamycin zur induktion der immunosuppression
DK234590D0 (da) Fremgangsmaade til behandling af retrovirusinfektioner
FI963638A7 (fi) Menetelmiä HIV-1-injektion diagnosoimiseksi ja hoitamiseksi
DE69016416D1 (de) Laserstrahlbehandlungsvorrichtung.
MX9200923A (es) Componente de guia de vidrio.
DE68913995D1 (de) Zusammensetzung zur behandlung progressiver myopie.
DE3785550D1 (de) Photosensible zusammensetzung mit verbesserter haftung, gegenstaende und verfahren.
IT1266849B1 (it) Programmatore analogico perfezionato per forni.
DE3669159D1 (de) Triazinderivate, verfahren zur herstellung dieser derivate und herbizide, welche diese derivate als wirksame komponente enthalten.
ES1023268Y (es) Pieza perfeccionada parajuegos de construccion.
DK224390D0 (da) Apparat til faeldning af mindre traeer
DE68914450D1 (de) Verfahren zur bekämpfung von fichtenborkenkäfern und zusammensetzung dafür.